ArticleFertility and sterility2017
Impact of tamoxifen therapy on fertility in breast cancer survivors.
Article in Fertility and sterility, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 3 syntheses or guidelines pooled it, 73 citations in OpenAlex.
- Tamoxifen and Fertility in Women with Breast Cancer: A Systematic Review on Reproductive Outcomes and Oncological Safety of Treatment Interruption.International journal of molecular sciences · 2025Pooled it
- Safety of pregnancy after breast cancer in young women with hormone receptor-positive disease: a systematic review and meta-analysis.ESMO open · 2023Pooled it
- Anti-Müllerian hormone as a marker of ovarian reserve and premature ovarian insufficiency in children and women with cancer: a systematic review.Human reproduction update · 2022Pooled it
- Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients.Journal of the National Cancer Institute · 2019Trial
- Reproductive Challenges in Mutated BRCA Gene Carriers: A Narrative Review.Current issues in molecular biology · 2026Review
- Assisted Reproductive Technology in Breast and Gynecologic Malignancies: Cancer Risk, Fertility Preservation, and Post-Treatment Reproductive Outcomes.Journal of clinical medicine · 2026Review
- Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.Current treatment options in oncology · 2026Review
- Time-Varying Hormonal Treatment and Metastasis-Free Survival Among ER+ Breast Cancer Patients: A Natural History Modelling Approach.Statistics in medicine · 2026Article
- Predictors of referral for fertility preservation counseling in patients diagnosed with cancer.Journal of assisted reproduction and genetics · 2026Article
- Fertility under fire: how chemotherapy harms the ovaries and the science fighting back?Journal of ovarian research · 2026Review
- Evaluating Trends in Fertility Counseling among Reproductive-Age Patients with Breast Cancer.Annals of surgical oncology · 2025Article
- A life put on hold? Navigating fertility-related considerations after cancer in adolescence and young adulthood (AYA).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Reduced reproductive potential in young healthy women with hereditary breast and/or ovarian cancer syndrome.Communications medicine · 2025Article
- Pregnancy after breast cancer treatment in young patients.Frontiers in oncology · 2025Article
- Balancing Fertility Preservation and Treatment Efficacy in (Neo)adjuvant Therapy for Adolescent and Young Adult Breast Cancer Patients: a Narrative Review.Current oncology reports · 2024Review
- Breast cancer Treatment and Fertility Preservation: A Narrative Review of Impacts, Strategies and Ethical Considerations.Current oncology reports · 2024Review
- Menstrual Blood Stem Cells-Derived Exosomes as Promising Therapeutic Tools in Premature Ovarian Insufficiency Induced by Gonadotoxic Systemic Anticancer Treatment.International journal of molecular sciences · 2024Review
- Patient-Related Awareness of Impact of Cancer-Directed Therapy on Fertility in Young Women Diagnosed of Breast Cancer.South Asian journal of cancer · 2024Article
- Review
- Impaired fertility in adenomyosis: a murine model reveals endometrial receptivity and progesterone resistance imbalances.Reproduction (Cambridge, England) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
objectiveTo determine whether tamoxifen use is associated with decreased ovarian reserve and decreased likelihood of having a child after a breast cancer diagnosis, using data from the Furthering Understanding of Cancer, Health, and Survivorship in Adult (FUCHSIA) Women Study.
designPopulation-based cohort study.
settingNot applicable. PATIENT(S): Three hundred ninety-seven female breast cancer survivors aged 22-45 years whose cancer was diagnosed between ages 20 and 35 years and who were at least 2 years after diagnosis; 108 survivors also participated in a clinic visit. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Time to first child after cancer diagnosis, clinical measures of ovarian reserve (antimüllerian hormone [AMH] and antral follicle count [AFC]) after cancer. RESULT(S): Women who had ever used tamoxifen were substantially less likely to have a child after the breast cancer diagnosis (hazard ratio [HR] 0.29; 95% confidence interval [CI], 0.16, 0.54) than women who had never used tamoxifen. After adjusting for age at diagnosis, exposure to an alkylating agent, and race, the HR was 0.25 (95% CI, 0.14, 0.47). However, after adjusting for potential confounders, women who had used tamoxifen had an estimated geometric mean AMH level 2.47 times higher (95% CI, 1.08, 5.65) than women who had never taken tamoxifen. Antral follicle count was also higher in the tamoxifen group compared with the tamoxifen nonusers when adjusted for the same variables (risk ratio 1.21; 95% CI, 0.84, 1.73). CONCLUSION(S): Breast cancer survivors who had used tamoxifen were less likely to have a child after breast cancer diagnosis compared with survivors who never used tamoxifen. However, tamoxifen users did not have decreased ovarian reserve compared with the tamoxifen nonusers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.